EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Inhibikase Therapeutics's enterprise value is $2.18 Mil.
Inhibikase Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Inhibikase Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Inhibikase Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Inhibikase Therapeutics was 172.84. The lowest was -8.47. And the median was 1.47.
IKT's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.145 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibikase Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Inhibikase Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's EV-to-Revenue falls into.
Inhibikase Therapeutics's current Enterprise Value is $2.18 Mil.
Inhibikase Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics's share price for today is $1.81.
Inhibikase Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Inhibikase Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKT has been successfully added to your 